CD274 and neoplasm: In contrast to other cancers such as melanoma, lung and bladder cancer, tumor tissue levels of programmed cell death ligand 1 (PD-L1) or the tumor mutational burden are insufficient to predict response to CPI treatment in mRCC [5–7].